Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) major shareholder Equity Fund L.P. Cardinal sold 275,728 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $8,183,607.04. Following the transaction, the insider owned 345,123 shares of the company’s stock, valued at approximately $10,243,250.64. The trade was a 44.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Guardian Pharmacy Services Stock Down 3.0%
GRDN stock opened at $35.41 on Friday. The business’s fifty day simple moving average is $32.74 and its two-hundred day simple moving average is $29.91. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $38.12. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 45.98 and a beta of 0.86.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last released its earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.10. The business had revenue of $397.62 million during the quarter, compared to the consensus estimate of $390.04 million. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. Research analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.
Institutional Trading of Guardian Pharmacy Services
Analysts Set New Price Targets
A number of brokerages recently weighed in on GRDN. Truist Financial boosted their price objective on shares of Guardian Pharmacy Services from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. UBS Group reaffirmed a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Stephens boosted their price target on Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, January 14th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $38.00.
Read Our Latest Report on GRDN
Trending Headlines about Guardian Pharmacy Services
Here are the key news stories impacting Guardian Pharmacy Services this week:
- Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
- Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
- Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
- Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
- Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
- Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
- Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
- Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
- Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
- Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
- Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
See Also
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
